Pharma acquisition news : US biotechnology company Biogen has made a deal with Pfizer to buy the latter’s neurology drug candidate PF-04958242, which is being developed for the treatment of a symptom associated with schizophrenia. The deal is potentially almost $600 million with an upfront payment of $75 million followed up by additional milestone payments […]
The post Biogen to acquire Pfizer neurology drug in a deal that could reach $600m appeared first on Business News Today.